Figure 2. Immunocytochemistry of F-actin, α-SMA, COL1A1, and fibronectin in hTM cells treated with TGF-β1 and TGF-β2. The human trabecular meshwork (hTM) cells were treated with 10 ng/ml of TGF-β1 and TGF-β2 for 24 h with or without the TGF-β inhibitor or the ROCK inhibitor. The panels show cells stained for F-actin (red), α-SMA (green), COL1A1 (red), and fibronectin (red) merged with 4’,6-diamidino-2-phenylindole (DAPI; blue) from left to right. The expression of F-actin was altered, and the expression of α-SMA, COL1A1, and fibronectin was increased by TGF-β1 and TGF-β2; these effects were attenuated by the TGF-β inhibitor or the ROCK inhibitor. Bar, 200 µm.